Download Sample
Add to CartGlobal Pertussis Infection Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product Type;
Reagents & Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella, and PCR Instruments.By End Users;
Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research Centers.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Pertussis Infection Testing Market (USD Million), 2021 - 2031
In the year 2024, the Global Pertussis Infection Testing Market was valued at USD 326.63 million. The size of this market is expected to increase to USD 491.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.
The Global Pertussis Infection Testing Market is experiencing significant growth as the demand for accurate and efficient diagnostic tools for pertussis, commonly known as whooping cough, continues to rise. Pertussis is a highly contagious respiratory disease caused by the Bordetella pertussis bacterium, which primarily affects infants, young children, and individuals with weakened immune systems. Despite the availability of vaccines, pertussis remains a major public health concern worldwide, with periodic outbreaks, especially in regions with suboptimal vaccination coverage. The increasing burden of pertussis, along with growing awareness about its potential complications, has led to a surge in demand for rapid, reliable diagnostic testing to detect the infection at early stages and improve treatment outcomes.
The global market for pertussis infection testing is primarily driven by the need for early detection and accurate differentiation of pertussis from other respiratory infections, particularly in infants and vulnerable populations. As symptoms such as prolonged coughing fits and difficulty breathing can overlap with other respiratory conditions like influenza, accurate and timely diagnosis is crucial for effective treatment. Several diagnostic methods are currently available, including traditional culture-based techniques, polymerase chain reaction (PCR) testing, serological assays, and rapid antigen detection tests. These innovations in diagnostic testing have played a critical role in improving the detection rate of pertussis, enabling healthcare providers to initiate timely interventions and reduce transmission.
In addition to increasing awareness and the need for better diagnostics, the pertussis infection testing market is also influenced by advancements in testing technologies. PCR-based tests, which offer higher sensitivity and faster results, are becoming more popular due to their ability to detect Bordetella pertussis DNA even in the early stages of infection. The rise of point-of-care (POC) testing and the growing trend toward home-based diagnostic kits further contribute to market expansion. As healthcare systems and diagnostic laboratories across the globe invest in improving testing infrastructure, the pertussis infection testing market is poised for sustained growth. Moreover, government initiatives aimed at improving vaccination coverage and monitoring pertussis outbreaks are expected to support market expansion, as robust diagnostic testing plays an essential role in disease surveillance and control strategies
Global Pertussis Infection Testing Market Recent Developments
-
In July 2023, the price of Quadracel, a DTaP-IPV vaccine produced by Sanofi Pasteur, the vaccine division of the French multinational pharmaceutical company Sanofi, was set at US$ 61.12 per single vial. Furthermore, emerging markets present an enticing opportunity for key players in the pertussis vaccine market.
-
In June 2021, GSK aimed to achieve significant growth and improved performance by focusing on research and development, as well as increasing commercial investments in vaccines and specialty medicines.
Segment Analysis
The Global Pertussis Infection Testing Market is segmented based on test type, end-user, and region, each of which plays a critical role in shaping the market dynamics. The test type segment includes PCR-based tests, serological tests, culture-based tests, and rapid antigen detection tests. PCR-based testing is expected to dominate the market due to its high sensitivity and specificity. It allows for the detection of Bordetella pertussis DNA even in the early stages of infection, making it the preferred choice for accurate diagnosis. PCR tests can also detect other pathogens that cause similar symptoms, providing comprehensive results. Rapid antigen detection tests are gaining traction due to their ability to deliver quick results, making them useful for point-of-care settings, though they are generally less sensitive than PCR tests. Serological and culture-based tests, while important, are slower and typically used in specific clinical contexts or for epidemiological studies.
In terms of end-users, the market is primarily driven by hospitals, diagnostic laboratories, and point-of-care settings. Hospitals and diagnostic labs are expected to account for the largest share of the market, as they have the infrastructure and resources to conduct a wide range of diagnostic tests, including advanced PCR and serological assays. The increasing adoption of point-of-care (POC) testing in outpatient clinics and home-based settings is creating new opportunities for growth. POC testing allows for rapid diagnosis at the site of care, improving access to timely treatment, particularly in remote or underserved areas. As healthcare systems increasingly focus on reducing patient wait times and improving the speed of diagnosis, the demand for POC testing solutions for pertussis will continue to rise.
Global Pertussis Infection Testing Segment Analysis
In this report, the Global Pertussis Infection Testing Market has been segmented by Product Type, End Users, and Geography.
Global Pertussis Infection Testing Market, Segmentation by Product Type
The Global Pertussis Infection Testing Market has been segmented by Product Type into Reagents and Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella and PCR Instruments.
The Global Pertussis Infection Testing Market is segmented by Product Type into several key categories: Reagents and Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella, and PCR Instruments. The Reagents and Kits segment holds a significant share of the market, as these are essential components in the diagnostic process for pertussis. These reagents and kits are used in various diagnostic tests, including PCR assays, ELISA tests, and antigen detection methods, and are critical for accurate and timely diagnosis. The continuous demand for high-quality reagents and testing kits, driven by the need for rapid and efficient pertussis detection, ensures the growth of this segment. As more healthcare facilities and diagnostic centers expand their testing capabilities, the demand for these essential components is expected to rise.
The Bordetella Pertussis IgM ELISA Test is another important segment, focusing on the detection of IgM antibodies specific to Bordetella pertussis. This test is widely used in diagnosing pertussis, especially in the later stages of infection, as the IgM antibodies typically appear after the onset of symptoms. The IgM ELISA test is preferred for its high sensitivity and ability to detect past infections. However, it has limitations in detecting early infections, which is why it is often used in conjunction with molecular tests like PCR. This segment is particularly significant in regions with high vaccination rates, where traditional diagnostic methods might be necessary for confirming suspected cases of pertussis.
The Instruments segment, which includes FluoroType Bordetella and PCR Instruments, is experiencing substantial growth as molecular diagnostics become the gold standard for detecting pertussis. FluoroType Bordetella is a relatively new innovation that offers rapid detection of Bordetella pertussis DNA through fluorescence-based PCR technology. This method provides faster results than traditional PCR while maintaining high sensitivity and specificity. The PCR Instruments segment is also crucial, as PCR remains the most accurate method for early-stage detection of pertussis. PCR instruments are widely adopted in clinical laboratories due to their ability to identify Bordetella pertussis DNA quickly and with high precision, even in asymptomatic or early-stage cases. As the demand for early and accurate diagnosis increases, the market for these advanced PCR-based instruments and testing solutions continues to expand, driving overall market growth.
Global Pertussis Infection Testing Market, Segmentation by End Users
The Global Pertussis Infection Testing Market has been segmented by End Users into Hospitals, Specialty Clinics, Diagnostic Laboratories and Research Centers.
The Global Pertussis Infection Testing Market is segmented by End Users into Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research Centers. Hospitals represent the largest end-user segment, owing to their well-established infrastructure, availability of skilled healthcare professionals, and advanced diagnostic equipment. Hospitals are the primary setting for patients with suspected pertussis infections, particularly in severe cases, such as in infants or immunocompromised individuals. These facilities typically have access to a wide range of diagnostic tests, including PCR, serological assays, and rapid antigen tests, which allow for accurate and timely diagnosis. The growing number of hospitals investing in advanced diagnostic technologies to improve the accuracy and speed of pertussis detection is expected to fuel the market's growth in this segment.
Specialty Clinics are another key segment in the pertussis infection testing market, driven by the increasing demand for specialized care in diagnosing respiratory diseases. Specialty clinics, particularly those focused on pediatric care, infectious diseases, and respiratory conditions, play an essential role in the detection and treatment of pertussis, especially in populations at higher risk, such as infants, elderly patients, and pregnant women. These clinics often have the capability to perform quick diagnostic tests, such as rapid antigen detection and PCR-based assays, allowing for rapid identification and intervention. The growing focus on pediatric healthcare and the rising prevalence of pertussis among vulnerable populations are expected to contribute to the increasing demand for pertussis testing in specialty clinics.
The Diagnostic Laboratories segment is another significant end-user in the pertussis infection testing market. Diagnostic laboratories, including commercial laboratories and academic research institutions, are key players in providing high-quality, reliable, and comprehensive testing services for pertussis. These labs are equipped with advanced testing technologies, such as PCR instruments, IgM ELISA tests, and culture-based methods, allowing for accurate and timely detection of Bordetella pertussis in various stages of infection. The demand for pertussis testing in diagnostic laboratories is growing as healthcare providers and public health agencies prioritize the surveillance and monitoring of respiratory diseases. Finally, Research Centers contribute to the market by focusing on the development of new diagnostic tools and improving existing technologies for better pertussis detection. Research centers are crucial for advancing knowledge on pertussis epidemiology, improving diagnostic techniques, and developing novel vaccines, thus fostering continued innovation within the market.
Global Pertussis Infection Testing Market, Segmentation by Geography
In this report, the Global Pertussis Infection Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Pertussis Infection Testing Market Share (%), by Geographical Region, 2024
The Global Pertussis Infection Testing Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. In North America, the market is expected to hold a significant share due to advanced healthcare infrastructure, high awareness levels regarding pertussis, and the presence of leading diagnostic companies. The United States, in particular, drives the growth of the pertussis testing market, supported by widespread vaccination campaigns, a high incidence of pertussis in certain populations (e.g., infants and the elderly), and the adoption of advanced diagnostic technologies such as PCR and ELISA tests. The region’s robust healthcare system and well-established diagnostic laboratories further contribute to the market's expansion, as hospitals and specialty clinics increasingly adopt molecular diagnostic tools for faster and more accurate detection.
In Europe, the pertussis infection testing market is also witnessing significant growth, driven by a combination of strong healthcare systems, regulatory frameworks, and increasing government efforts to improve vaccination rates and disease surveillance. The European market benefits from high awareness about pertussis and a strong emphasis on early detection and prevention. Countries such as Germany, the UK, and France are leading the market, with a growing number of healthcare institutions incorporating advanced diagnostic methods, including PCR-based testing, into their clinical practices. The European Union’s initiatives to monitor and control infectious diseases, coupled with increasing demand for accurate pertussis diagnostics, provide further impetus for market growth in this region.
The Asia Pacific region is expected to experience the highest growth rate in the Global Pertussis Infection Testing Market over the coming years. This growth is attributed to increasing healthcare investments, a rising prevalence of pertussis in several countries, and improving access to diagnostic technologies in emerging economies such as China, India, and Japan. Rapid urbanization, higher healthcare awareness, and expanding healthcare infrastructure in these countries are contributing to the increased adoption of pertussis testing. Although Middle East and Africa and Latin America have more moderate market growth, both regions are seeing gradual improvements in healthcare access and diagnostic capabilities. While economic challenges and lower vaccination coverage may limit growth, ongoing public health initiatives aimed at controlling infectious diseases are likely to drive demand for pertussis testing in these regions. The rising focus on disease surveillance and diagnostic technology improvements will continue to support the market's expansion in these developing areas.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Pertussis Infection Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Rising Incidence of Pertussis Outbreaks
- Demand for Early and Accurate Diagnosis
-
Advancements in Diagnostic Technologies- The Global Pertussis Infection Testing Market is the advancements in diagnostic technologies, which have significantly enhanced the ability to detect pertussis more accurately and efficiently. Over the past few years, there has been a shift toward more rapid and precise testing methods. The introduction of polymerase chain reaction (PCR) technology has been a game-changer in pertussis diagnosis. PCR allows for the detection of Bordetella pertussis DNA in patient samples, even in the early stages of infection when traditional diagnostic methods, such as culture tests, might fail to detect the pathogen. PCR-based tests are highly sensitive and specific, enabling clinicians to diagnose pertussis quickly and with greater accuracy, which is crucial for effective treatment and reducing transmission.
In addition to PCR, molecular diagnostics such as FluoroType Bordetella have emerged as another significant advancement. This technology utilizes fluorescence-based PCR techniques, offering even faster results compared to traditional PCR, making it ideal for point-of-care (POC) settings. These innovations have improved the turnaround time for results, allowing for quicker diagnosis, which is particularly important in hospitals and emergency settings where time-sensitive decisions are necessary. The ability to conduct tests more rapidly also facilitates better patient management and reduces the burden on healthcare systems, making diagnostic procedures more efficient and less expensive over time.
The growing adoption of serological tests and rapid antigen detection tests has also contributed to advancements in pertussis diagnosis. While these methods are not as sensitive as PCR, they offer several advantages, such as affordability, simplicity, and the ability to be used in remote or resource-limited areas. These tests can quickly detect antibodies or antigens related to Bordetella pertussis in patients, providing valuable information for epidemiological surveillance and outbreak management. The continued innovation and refinement of these diagnostic technologies ensure that healthcare providers have a wider array of tools at their disposal to detect pertussis more effectively, ultimately driving the growth of the pertussis infection testing market. As these technologies continue to evolve, they will likely make testing even more accessible, improving both the speed and accuracy of pertussis diagnoses across various healthcare settings.
Restraints:
- High Cost of Advanced Diagnostic Tests
- Lack of Standardization in Diagnostic Methods
-
Shortage of Skilled Labor and Infrastructure in Developing Regions- The growth of the Global Pertussis Infection Testing Market is the shortage of skilled labor and infrastructure in developing regions. Many low- and middle-income countries face significant challenges in building and maintaining the necessary infrastructure for advanced diagnostic testing. While molecular diagnostic technologies like PCR and serological assays have revolutionized pertussis detection, these technologies require specialized equipment and trained personnel to operate them effectively. In many developing regions, healthcare systems often lack the resources, laboratory facilities, and diagnostic tools needed to conduct these sophisticated tests, which can delay the timely identification and treatment of pertussis infections. As a result, the adoption of advanced testing methods is slower in these regions compared to developed markets.
In addition to infrastructure challenges, the shortage of skilled labor is a critical issue. Performing high-quality pertussis tests, particularly PCR and other molecular diagnostics, requires highly trained laboratory technicians and healthcare professionals with expertise in handling complex diagnostic instruments and interpreting test results. However, many developing countries face a lack of properly trained professionals, leading to suboptimal test results, misdiagnoses, or even the inability to offer certain diagnostic tests. This shortage of skilled labor is exacerbated by issues like brain drain, where trained healthcare workers migrate to developed countries for better opportunities, further undermining diagnostic capabilities in their home countries. The inability to provide accurate and timely diagnosis of pertussis due to this shortage of trained personnel limits the effectiveness of diagnostic interventions and slows market growth in these regions.
The lack of healthcare infrastructure in many parts of the world, particularly in rural or remote areas, compounds the problem. Even in countries with relatively advanced urban healthcare systems, access to diagnostic tests for pertussis can be limited in more remote regions. The absence of diagnostic laboratories, appropriate cold-chain systems for storing reagents, and reliable power sources makes it difficult to implement large-scale testing for pertussis. This lack of infrastructure also hampers the widespread deployment of rapid antigen detection tests and point-of-care diagnostic solutions, which could otherwise provide more accessible and affordable alternatives in these underserved regions. As a result, the growing burden of pertussis infections in developing areas is not matched by adequate diagnostic testing, limiting the impact of new technologies and slowing the overall growth of the global market for pertussis infection testing. Addressing these infrastructure and workforce challenges is essential for unlocking the potential of the pertussis testing market in developing regions.
Opportunities:
- Growth in Point-of-Care (POC) and Home-Based Testing Solutions
- Technological Innovations in PCR and Molecular Testing
-
Increase in Vaccination and Monitoring Programs- The Global Pertussis Infection Testing Market is the increase in vaccination and monitoring programs aimed at controlling pertussis outbreaks and improving disease surveillance. As governments and health organizations recognize the importance of preventing pertussis, there has been a growing push for more comprehensive vaccination campaigns, particularly targeting infants, adolescents, and vulnerable populations. Enhanced vaccination efforts not only reduce the incidence of pertussis but also raise awareness of the disease, leading to an increased demand for accurate diagnostic testing. As more people are vaccinated, there is also a greater emphasis on monitoring the effectiveness of vaccination programs and identifying any outbreaks, which in turn fuels the need for efficient testing methods to track the presence of the Bordetella pertussis bacterium in populations.
The expansion of national and international monitoring programs provides a unique opportunity for the pertussis infection testing market by promoting the use of diagnostic tests as part of routine surveillance activities. Many countries are now implementing more rigorous disease monitoring systems that include regular screening for pertussis in both clinical settings and during epidemiological studies. This surge in monitoring efforts allows health authorities to detect outbreaks early and take appropriate actions to mitigate transmission. Testing for pertussis has thus become a critical component of global public health strategies, particularly in countries where vaccination rates may be suboptimal or where pertussis outbreaks are more common. As surveillance programs expand, the demand for accurate and reliable pertussis diagnostic tests continues to grow, providing significant opportunities for growth in the market.
The monitoring programs offer a platform for innovation in diagnostic testing, as they encourage the development of more efficient and cost-effective diagnostic tools. Governments and public health organizations are increasingly focused on improving disease surveillance, which presents an opportunity for diagnostic companies to collaborate with these institutions to develop point-of-care (POC) solutions, rapid antigen tests, and molecular diagnostics that can be used in resource-limited settings. The rise of real-time data collection and digital health technologies also opens up new avenues for implementing more accessible testing methods. The integration of diagnostic testing with vaccination and monitoring programs ensures that diagnostic tools are not only used during clinical visits but are also incorporated into routine surveillance, thereby increasing their reach and utilization. This symbiotic relationship between vaccination initiatives, disease monitoring, and diagnostic testing will continue to drive the growth of the pertussis infection testing market, particularly in regions with a high burden of disease or where vaccination programs are expanding.
Competitive Landscape Analysis
Key players in Global Pertussis Infection Testing Market include,
- Thermo Fisher Scientific, Inc.
- BioMérieux SA
- Abbott Laboratories
- Cepheid (Danaher Corporation)
- Hologic, Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
- Becton, Dickinson and Company (BD)
- Roche Diagnostics
- DiaSorin S.p.A.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By End Users
- Market Snapshot, By Region
- Global Pertussis Infection Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Incidence of Pertussis Outbreaks
- Demand for Early and Accurate Diagnosis
- Advancements in Diagnostic Technologies
- Restraints
- High Cost of Advanced Diagnostic Tests
- Lack of Standardization in Diagnostic Methods
- Shortage of Skilled Labor and Infrastructure in Developing Regions
- Opportunities
- Growth in Point-of-Care (POC) and Home-Based Testing Solutions
- Technological Innovations in PCR and Molecular Testing
- Increase in Vaccination and Monitoring Programs
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Pertussis Infection Testing Market, By Product Type, 2021 - 2031 (USD Million)
- Reagents & Kits
- Bordetella Pertussis IgM ELISA Test
- Instruments
- FluoroType Bordetella
- PCR Instruments.
- Global Pertussis Infection Testing Market, By End Users, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Research Centers
- Global Pertussis Infection Testing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Pertussis Infection Testing Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific, Inc.
- BioMérieux SA
- Abbott Laboratories
- Cepheid (Danaher Corporation)
- Hologic, Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
- Becton, Dickinson and Company (BD)
- Roche Diagnostics
- DiaSorin S.p.A.
- Company Profiles
- Analyst Views
- Future Outlook of the Market